Maridebart cafraglutide (MariTide)
Metabolic Health · GLP-1 agonist + GIP antagonist
Tier B
What this is
Amgen. Phase 2 (Jastreboff NEJM 2025, n=592, NCT05669599): obesity cohort -12.3% to -16.2% body weight at 52 weeks vs -2.5% placebo; T2D cohort -8.4% to -12.3% with HbA1c -1.2 to -1.6 percentage points. Once-monthly dosing is the differentiator vs weekly GLP-1s. Counterintuitive that BOTH GIP agonism (tirzepatide) AND antagonism (MariTide) produce additive weight loss with GLP-1 — pharmacology not fully resolved.
Mechanism
Long-acting peptide-antibody conjugate combining GLP-1 receptor agonism with GIP receptor antagonism (the inverse of tirzepatide's GIP agonism); enables once-monthly dosing
Dose & route
140-420 mg SC every 4-8 weeks; titration schedules vary
Citations
- https://doi.org/10.1056/NEJMoa2504214
- https://doi.org/10.3390/jcm14113812
- https://doi.org/10.1056/NEJMc2514331
- https://pubmed.ncbi.nlm.nih.gov/40521869/
- https://doi.org/10.1007/s12325-026-03576-6
- https://doi.org/10.20944/preprints202512.1726.v1
- https://pubmed.ncbi.nlm.nih.gov/41174263/
- https://doi.org/10.17863/cam.129561
- https://doi.org/10.3390/biomedicines14040778
Links go to the source. If a link is dead or you want something re-checked, let me know.
This is an independent synthesis of published research by a non-clinician. Scores are opinions supported by citations, not prescriptions. See the full disclaimer and methodology for how this score was produced and what it does and doesn't mean.